A Phase 1, Repeat Dose Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection in Japanese Subjects with Advanced Hepatic Fibrosis (METAVIR F3-4)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2017
At a glance
- Drugs ND L02 s0201 (Primary)
- Indications Hepatic fibrosis
- Focus Adverse reactions
- Acronyms METAVIR F3-4
- Sponsors Nitto Denko
- 16 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Apr 2017 Planned End Date changed from 30 Apr 2017 to 31 Dec 2017.
- 12 Jul 2016 Planned End Date changed from 31 Aug 2016 to 30 Apr 2017.